Back to top

LACOG 1018 – PALBO in Ovarian Cancer

  /    /  LACOG 1018 – PALBO in Ovarian Cancer

Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer

Type of Study: Clinical Trial

Sponsor / Support: LACOG

Primary Objectives: To evaluate the efficacy, assessed by 12 weeks progression-free survival (PFS), of Palbociclib plus Letrozole in ER/PR positive serous ovarian cancer that progressed on second line chemotherapy.

Design: Multicenter, single arm, phase II clinical trial.

Sample Size: 39 patients

Principal Investigator: Fernanda Bronzon Damian

Countries LATAM: Brazil Identifier: NCT03936270 

The study is open to patients participation in the following research sites:

BP - A Beneficência Portuguesa de São Paulo / São Paulo / SP / Brazil

UFMG - Universidade Federal de Minas Gerais / Belo Horizonte / MG / Brazil

INCA - Instituto Nacional de Câncer / Rio de Janeiro / RJ / Brazil

CPO-RS - Centro de Pesquisa em Oncologia / Porto Alegre / RS / Brazil

ICESP - Instituto do Câncer do Estado de São Paulo / São Paulo / SP / Brazil